Wire flash
CAS Space and Guangzhou Lab plan suborbital flight verification in Q1 2027
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
According to a report from Jin10 on September 28, CAS Space (Zhongke Yuhang) and the Guangzhou Laboratory are jointly developing and researching space-based pharmaceutical payloads, and plan to jointly conduct space pharmaceutical scenario verification. The first batch of payloads is scheduled to conduct suborbital flight verification in the first quarter of 2027, using the Lihong-2 reusable launch vehicle. The mission will implement protein and small-molecule drug crystallization experiments and carry out preliminary technical verification of space pharmaceutical equipment. The report was sourced from Securities Times.
Source report
September 28 (Jin10 Data) — Zhongke Yuhang (China Aerospace Science and Industry Corporation) and the Guangzhou Laboratory have recently initiated a joint research and development effort focused on space-based pharmaceutical payloads, with plans to jointly conduct scenario validation for space drug manufacturing.
The first batch of payloads is scheduled to undergo suborbital flight validation aboard the Lihong-2 reusable launch vehicle in the first quarter of 2027. The mission will include:
- Protein and small-molecule drug crystallization experiments
- Preliminary technology validation for space-based pharmaceutical equipment
(Source: Securities Times)
Source
金十数据Eastern
Part of this Story
CAS Space and Guangzhou Lab to test space-based drug manufacturing on 2027 Lihong-2 flight